[The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia]
- PMID: 27431075
- PMCID: PMC7348344
- DOI: 10.3760/cma.j.issn.0253-2727.2016.06.011
[The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia]
Abstract
Objective: To investigate the prognostic significance of proportion of the blasts in bone marrow on day 14 (D14) during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia (Ph (-) ALL).
Methods: Newly diagnosed Ph (-) ALL patients with bone marrow morphology analysis on day 14 during induction chemotherapy were analyzed retrospectively. The proportion of the D14 blasts which had an impact on achieving a CR by the first induction chemotherapy and outcomes were determined by ROC curve.
Results: 166 ALL patients including 94 male and 72 female were analyzed. The median age was 32 years (range, 18-64 years). The CR rate by the first induction chemotherapy was 74.7% with a total CR rate as 93.3%. By ROC analysis, 7.5% of the D14 blasts had the best sensitivity and specificity. The patients with D14 blasts ≥7.5% had lower CR rates after the first and overall induction chemotherapy compared with those with D14 blasts <7.5% (42.7% vs 85.9%, P<0.001 and 75.9% vs 95.6%, P=0.001 respectively). The probabilities of 5-year disease free survival (DFS) and 5-year overall survival (OS) were higher in the patients with D14 blasts<7.5% than those with D14 blasts ≥7.5% (49.8% vs 29.6%, P=0.006 and 52.4% vs 32.6%, P=0.010 respectively). Multivariate analysis showed that higher WBC or central nervous system leukemia at diagnosis, D14 blasts ≥7.5%, no CR after the first induction chemotherapy and receiving consolidation and maintenance chemotherapy rather than transplant were associated with poor outcomes.
Conclusions: Higher proportion of D14 blasts in bone marrow during the first induction therapy indicated poor prognosis in adult Ph(-) ALL.
目的: 探讨成人Ph染色体阴性急性淋巴细胞白血病(Ph−ALL)诱导治疗第14天(D14)骨髓原始细胞比例与获得完全缓解(CR)和预后的关系。
方法: 回顾分析166例初治Ph−ALL患者,通过ROC曲线确定影响诱导治疗4周达CR的D14骨髓原始细胞比例。
结果: 166例Ph−ALL患者,男94例,女72例,中位年龄32(18~64)岁。诱导治疗4周CR率为74.7%,总CR率为93.3%。存活者中位随访32(2~175)个月,5年无病生存(DFS)和总体生存(OS)率分别为45.6%和47.2%。D14骨髓原始细胞≥0.075组与<0.075组相比,4周CR率(42.7%对85.9%,P<0.001)和总CR率(75.9%对95.6%,P=0.001)显著降低,5年DFS率(29.6%对49.8%,P=0.006)和OS率(32.6%对52.4%,P=0.010)均显著降低。多因素分析显示,发病时高白细胞计数、存在中枢神经系统白血病、D14骨髓原始细胞≥0.075、诱导治疗4周未达CR、CR后接受化疗而非移植是影响DFS和OS的不利因素。
结论: 成人Ph−ALL患者诱导化疗D14骨髓原始细胞比例较高是影响获得CR和总体预后的不利因素。
Figures
Similar articles
-
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.Cancer. 2016 Dec 15;122(24):3812-3820. doi: 10.1002/cncr.30262. Epub 2016 Aug 10. Cancer. 2016. PMID: 27508525 Free PMC article.
-
Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.J Clin Oncol. 1989 Dec;7(12):1807-15. doi: 10.1200/JCO.1989.7.12.1807. J Clin Oncol. 1989. PMID: 2685179 Clinical Trial.
-
Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):204-209. doi: 10.1016/j.clml.2018.01.007. Epub 2018 Jan 31. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29433979
-
Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?Am J Hematol. 2016 Mar;91(3):277-82. doi: 10.1002/ajh.24271. Epub 2016 Jan 11. Am J Hematol. 2016. PMID: 26663264
-
Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. doi: 10.1097/00043426-200112000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11902303 Review.
References
-
- Alvarnas JC, Brown PA, Advani A, et al. NCCN clinical practice guidelines in oncology. Acute lymphoblastic leukemia. National Comprehensive Cancer Network, Inc; 2016. Version 1. - PubMed
-
- Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial[J] Blood. 2007;109(8):3189–3197. doi: 10.1182/blood-2006-10-051912. - DOI - PubMed